March 27, 2017 12:02 AM ET

Pharmaceuticals

Company Overview of Actavis UK Ltd

Company Overview

Actavis UK Ltd develops, manufactures, and distributes generic, branded, and biosimilar pharmaceutical products. It offers alenvona and cleosensa tablets, neotigason tablets, paracetamol solutions (for infusion), over-the-counter products, and fentanyl transdermal patch solutions. The company provides its products for the treatment of diseases in central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory, and anti-infective therapeutic categories. It serves patients and healthcare professionals worldwide. The company was founded in 1903 and is based in Barnstaple, United Kingdom with manufacturing and distribution facilities in the United Kingdom and inter...

Whiddon Valley

Barnstaple,  EX32 8NS

United Kingdom

Founded in 1903

Phone:

44 12 7131 1200

Fax:

44 12 7134 6106

Key Executives for Actavis UK Ltd

Managing Director - UK
Executive Director of Finance & Information Technology
Managing Director of Operations
Senior Vice President and President of UK & Ireland
Executive Director of Human Resources
Compensation as of Fiscal Year 2016.

Actavis UK Ltd Key Developments

Actavis UK Ltd Wins GBP 8.4 Million Multiple Awardees Contract

Actavis UK Ltd. won a GBP 8.4 million multiple awardees contract award from The Common Services Agency (more commonly known as NHS National Services Scotland) for the supply of a range of oncology generic medicines.

Actavis UK Ltd Wins GBP 28,784 Multiple Awardees Contract for Supplying Oncology Generic Medicines

Actavis UK Ltd. won a GBP 28,784 multiple awardees contract award from The Common Services Agency (more commonly known as NHS National Services Scotland) ('the Authority') for the supply of a range of oncology generic medicines (Vinorelbine Injection). This Framework Agreement is for the supply of a range of Oncology Generic Medicines to NHS Scotland.

Actavis UK Wins £136,203 Multiple Awardees Contract for Supplying Oncology Generic Medicines

Actavis UK Ltd. won a £136,203 multiple awardees contract award from The Common Services Agency (more commonly known as NHS National Services Scotland) for the supply of a range of oncology generic medicines (Bendamustine Powder For Solution For Infusion) (Contract Award Notice No.: 2017/S 016-025695; Lot No.: 1).

Similar Private Companies By Industry

Company Name Region
Abbey Pharma Limited Europe
Absynth Biologics Limited Europe
Acacia Pharma Limited Europe
AccentBio Ltd. Europe
Aclar Limited Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Actavis UK Ltd, please visit www.actavis.co.uk. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.